{"id":"W3043096450","doi":"10.1200/jco.20.00147","title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Puma Biotechnology; American Society of Clinical Oncology","keywords":"Capecitabine; Medicine; Lapatinib; Internal medicine; Neratinib; Hazard ratio; Metastatic breast cancer; Clinical endpoint; Gastroenterology; Oncology; Cancer; Breast cancer; Trastuzumab; Randomized controlled trial; Confidence interval; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001399587,0.001155057,0.002322881,0.0002823795,0.0003139296,0.001089244,0.0007766474,0.0009474041,0.003846171],"category_scores_gemma":[0.001066257,0.0003715588,0.001553419,0.0002775156,0.0006478847,0.0008200211,0.0003431238,0.002193504,0.0006582462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008199223,"about_ca_system_score_gemma":0.001266686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008271099,"about_ca_topic_score_gemma":0.00335818,"domain_scores_codex":[0.9996384,0.0001657175,0.00003076606,0.00007101773,0.00003306977,0.00006097772],"domain_scores_gemma":[0.9995153,0.0001044861,0.0000940595,0.00002900616,0.00002762927,0.0002295606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9335099,0.01308779,0.0009071332,0.0009876717,0.001156408,0.00009374262,0.00007673373,0.00110817,0.007087073,0.0001657638,0.001722219,0.04009729],"study_design_scores_gemma":[0.8802244,0.1137568,0.002640752,0.00005492445,0.0004455209,0.0001053788,0.00002802333,0.0006868563,0.0006536847,0.0001823465,0.001202831,0.00001840365],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857437,0.005827641,0.0004536258,0.0008320436,0.0004950076,0.002754722,0.0009033884,0.00009775464,0.002892107],"genre_scores_gemma":[0.9858791,0.003590112,0.001077495,0.001164282,0.0003472048,0.0026507,0.001148659,0.00001894482,0.00412348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003846171,"threshold_uncertainty_score":0.01286674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1286213107058051,"score_gpt":0.467998518340425,"score_spread":0.3393772076346199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}